Articles Referencing SGEN
Biotech Companies See Insider Purchases: CEO Phillip Frost Increases Stake in OPKO and Felix Baker Buys ACADIA
5/20/2013, 11:20 am from Minyanville in Investing, Stocks
Welcome to our daily roundup of top insider trades. Here's a
look at the most significant inside sales and purchases filed with
the SEC on Friday, May 17, 2013. Purchases: Felix Baker, a... Read >>
SGEN's Adcetris under FDA Review - Analyst Blog
5/16/2013, 4:29 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) recently
announced that the US Food and Drug Administration (FDA) has
accepted its supplemental biologics license application (sBLA)
seeking approval of... Read >>
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
5/8/2013, 10:25 am from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) reported first
quarter 2013 net loss per share of 14 cents, narrower than the
Zacks Consensus Estimate of a loss of 19 cents, but wider than the
year-ago... Read >>
Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy
5/7/2013, 1:53 pm from David Moenning in Investing, Investing Ideas, Stocks, US Markets
SoTM Bull's Eye Report - Today's Most Compelling Buy Tuesday, May 7, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>
Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick
4/26/2013, 3:20 pm from David Moenning in Investing, Investing Ideas, Stocks, US Markets
SoTM Bull's Eye Report - Today's Most Compelling Buy Friday, April 26, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>
Astellas, Ambrx Tie-Up on ADC - Analyst Blog
4/5/2013, 6:09 pm from Zacks.com in Investing, Business, Stocks
Astellas Pharma, Inc. ( ALPMY ) recently
announced a deal with Ambrx Inc. for the discovery and development
of novel antibody drug conjugates (ADC). Terms of the Deal As per the... Read >>
Takeda Files Adcetris in Japan - Analyst Blog
3/27/2013, 3:26 pm from Zacks.com in Investing, Business, Stocks
Takeda Pharmaceutical Company Limited ( TKPYY ) and its
subsidiary, Millennium, recently announced the submission of a new
drug application (NDA) to the Ministry of Health, Labour... Read >>
SGEN Seeks Adcetris Label Expansion - Analyst Blog
3/19/2013, 7:15 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) recently
announced the submission of a supplemental biologics license
application (sBLA) to the US Food and Drug Administration (FDA) for
the use of Adcetris... Read >>
SGEN Narrows Loss, Sales Rise - Analyst Blog
2/13/2013, 9:58 am from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) reported fourth
quarter 2012 net loss per share of 9 cents, narrower than the Zacks
Consensus Estimate of a loss of 13 cents and the year-ago loss of
24... Read >>
After-Hours Earnings Report for February 12, 2013 : FTI, RAX, WU, FRT, WSH, DDR, CLF, ACC, HCC, GWR, SGEN, SKT
2/12/2013, 2:00 pm from NASDAQ.com News in News Headlines, Earnings
The following companies are expected to report earnings after
hours on 02/12/2013. Visit our Earnings
Calendar for a full list of expected earnings releases. FMC Technologies, Inc. ( FTI )... Read >>
Canada Approves Seattle Genetics' Adcetris - Analyst Blog
2/4/2013, 5:44 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics Inc. ( SGEN ) recently
received approval from Health Canada for its oncology drug,
Adcetris (brentuximab vedotin). Adcetris has been approved under
Health Canada's Notice... Read >>
Data From SGEN on Cancer Candidate - Analyst Blog
1/29/2013, 1:00 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) recently
presented interim results from a phase I study which is evaluating
ASG-5ME for the treatment of metastatic pancreatic ductal
adenocarcinoma (PDA).... Read >>
SGEN/Takeda's Adcetris Progresses - Analyst Blog
1/25/2013, 4:30 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics Inc. ( SGEN ) and
Takeda Pharmaceutical Company Limited ( TKPYY ) recently
announced the commencement of a global phase III study (ECHELON-2)
on their oncology... Read >>
This Stock Could be Perfect for the "Dividend Decade"
1/8/2013, 12:30 pm from StreetAuthority in Investing, Investing Ideas, Stocks
If you're a regular StreetAuthority reader, then you've probably
heard of the "dividend decade," a prediction that in the 10 years,
therewill be no gain in the broadermarket .... Read >>
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN
9/10/2012, 10:33 am from GuruFocus in Investing
According to GuruFocus Insider Data , the largest CFO sells
during the past week were: Seattle Genetics Inc., Profire Energy
Inc., Marriott International Inc, Express Scripts Holdings... Read >>